ASLAN Pharmaceuticals (ASLN) said Monday that Nasdaq's Listing Qualifications Department has informed that it was delisting the company's securities because it did not meet the $1 bid price and $2.5 million shareholders' equity requirements for continued listing.
The biopharmaceutical firm said it has decided not to appeal a hearing before the regulator's Hearings Panel.
Shares of the company were down 43% in recent Monday premarket activity.
Price: 1.5200, Change: -1.00, Percent Change: -39.68
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments